H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why?
On January 26, TheFly reported that H.C. Wainwright raised its price target on Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) from $102 to $130 while maintaining its Buy rating.





